María Quindós
About
María Quindós is a scholar working on Oncology, Molecular Biology and Epidemiology.
According to data from OpenAlex, María Quindós has authored 22 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in María Quindós's work include Neuroendocrine Tumor Research Advances (3 papers), Glioma Diagnosis and Treatment (3 papers) and Neuroblastoma Research and Treatments (3 papers). María Quindós is often cited by papers focused on Neuroendocrine Tumor Research Advances (3 papers), Glioma Diagnosis and Treatment (3 papers) and Neuroblastoma Research and Treatments (3 papers). María Quindós collaborates with scholars based in Spain, United States and Montenegro. María Quindós's co-authors include Luis Antón-Aparicio, Mar Haz‐Conde, Lourdes Calvo, Margarita Reboredo, M. Blanco, Manuel Valladares‐Ayerbes, Angélica Figueroa, Isabel Santamarina, María José Lorenzo-Patiño and Juan Fernández‐Tajes and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.
In The Last Decade
María Quindós
21 papers receiving 445 citations
Peers
María Quindós
Taekyu Lim South Korea
Curt J. Essenburg United States
Ivo Buchhalter Germany
Jessica Giorcelli Italy
Kerstin Wenzl United States
Greg Friberg United States
Kate E Lines United Kingdom
Sara Molatore Italy
Estelle Daudigeos‐Dubus France
Huiqing Wu United States
Citations per year, relative to María Quindós María Quindós (= 1×)
peers
Taekyu Lim
Countries citing papers authored by María Quindós
Since
Specialization
Citations
This map shows the geographic impact of María Quindós's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Quindós with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Quindós more than expected).
Fields of papers citing papers by María Quindós
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by María Quindós. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Quindós. The network helps show where María Quindós may publish in the future.
Co-authorship network of co-authors of María Quindós
This figure shows the co-authorship network connecting the top 25 collaborators of María Quindós. A scholar is included among the top collaborators of María Quindós based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Quindós. María Quindós is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Matito, Judit, María Quindós, Claudia Valverde, et al.. (2025). Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway. JCO Precision Oncology. 9(9). e2400497–e2400497.
2.
González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to melanoma drugs in Spain: a cross-sectional survey. Clinical & Translational Oncology. 26(10). 2572–2583.
3.
Manso, Luís, Ignacio A. Romero, Luisa Sánchez‐Lorenzo, et al.. (2024). SEOM-GEICO Clinical Guidelines on cervical cancer (2023). Clinical & Translational Oncology. 26(11). 2771–2782.
4.
González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clinical & Translational Oncology. 27(1). 386–391.
5.
Cueva, Juan, Yolanda García García, Alfonso Yubero, et al.. (2023). #869 Niraparib maintenance therapy in patients aged 75 years and older with platinum-sensitive recurrent ovarian cancer: a subgroup assessment of the GEICO-88R study. A28.1–A28.
6.
Barretina-Ginesta, Maria-Pilar, María Quindós, Lydia Gaba, et al.. (2022). SEOM-GEICO clinical guidelines on endometrial cancer (2021). Clinical & Translational Oncology. 24(4). 625–634.
7.
Martín-Liberal, Juan, María Quindós, Almudena García‐Castaño, et al.. (2021). 1088P Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901 - DESCRIBE-AD). Annals of Oncology. 32. S900–S901.
8.
Palacio, Isabel, Cristina Churruca, Beatriz Pardo, et al.. (2021). 674 Niraparib as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a GEICO study within the Spanish extended access program. A261.1–A261.
9.
Sepúlveda-Sánchez, Juan Manuel, María Ángeles Vaz Salgado, Carmen Balañá, et al.. (2017). Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro-Oncology. 19(11). 1522–1531.
10.
Lamas‐Maceiras, Mónica, et al.. (2015). High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. Oxidative Medicine and Cellular Longevity. 2016(1). 5845061–5845061.
11.
Sepúlveda-Sánchez, Juan Manuel, María Ángeles Vaz Salgado, Marta Gil, et al.. (2015). 2902 GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation. European Journal of Cancer. 51. S585–S585.
12.
García‐Carbonero, Rocio, Roberto García‐Figueiras, Alberto Carmona‐Bayonas, et al.. (2015). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer and Metastasis Reviews. 34(4). 823–842.
13.
Sepúlveda-Sánchez, Juan Manuel, María Ángeles Vaz Salgado, Aurelio Hernández‐Laín, et al.. (2014). GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.. Journal of Clinical Oncology. 32(15_suppl). TPS2110–TPS2110.
14.
Martín‐Algarra, Salvador, Vincent Soriano, Josep Malvehy, et al.. (2014). Treatment Patterns of Adjuvant Interferon Alfa-2B (Ifn-&Agr;2B) for High-Risk Melanoma. a Retrospective Study of the Grupo Español Multidisciplinar De Melanoma (Gem). Annals of Oncology. 25. iv389–iv389.
15.
Blanco, M., Margarita Reboredo, Mar Haz‐Conde, et al.. (2014). Circulating Levels of GDF15, MMP7 and miR-200c as a Poor Prognostic Signature in Gastric Cancer. Future Oncology. 10(7). 1187–1202.
16.
Martín-Richard, Marta, Bartomeu Massutí, Vicente Alonso, et al.. (2013). Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 13(1). 427–427.
17.
Valladares‐Ayerbes, Manuel, Margarita Reboredo, María José Lorenzo-Patiño, et al.. (2012). Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. Journal of Translational Medicine. 10(1). 186–186.
18.
Antolín, Silvia, et al.. (2010). Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine. Clinical & Translational Oncology. 12(6). 450–452.
19.
García‐Campelo, Rosario, et al.. (2010). Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma. Anti-Cancer Drugs. 21(Supplement 1). S13–S15.
20.
Díaz‐Prado, Silvia, Daniel Ayude, Rosario García Campelo, et al.. (2008). In Silico and In Vitro Analysis of Small Breast Epithelial Mucin as a Marker for Bone Marrow Micrometastasis in Breast Cancer. Advances in experimental medicine and biology. 617. 331–339.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Taekyu Lim Breakdown of academic impact, for papers by Curt J. Essenburg Breakdown of academic impact, for papers by Ivo Buchhalter Breakdown of academic impact, for papers by Jessica Giorcelli Breakdown of academic impact, for papers by Kerstin Wenzl Breakdown of academic impact, for papers by Greg Friberg Breakdown of academic impact, for papers by Kate E Lines Breakdown of academic impact, for papers by Sara Molatore Breakdown of academic impact, for papers by Estelle Daudigeos‐Dubus Breakdown of academic impact, for papers by Huiqing Wu